Telomerase reverse transcriptase (TERT) promoter mutations occur in 60–80% of all urothelial bladder cancers (UBC) independent of tumor stage and grading thus, represent the most frequent alteration in this tumor entity [1]. Here, TERT is linked to neoplasm.